Showing results (2021-2030 of 2,093) with videos related to

Sort By:
Pageof 210
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2006
Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation statusMichael S Gordon, Daniela Matei, Carol Aghajanian, et al.
BJU International|May 12, 2019
Targeted deep sequencing of urothelial bladder cancers and associated urinary DNA: a 23-gene panel with utility for non-invasive diagnosis and risk stratificationDouglas G Ward, Naheema S Gordon, Rebecca H Boucher, et al.
Respiratory Care|January 4, 2024
Home Oxygen After Hospitalization for COVID-19: Results From the Multi-Center OXFORD StudyMichael B Freedman, Yoo Jin Kim, Ramandeep Kaur, et al.
Drug and Alcohol Dependence|November 10, 2018
Approaches for creating comparable measures of alcohol use symptoms: Harmonization with eight studies of criminal justice populationsAndrea M Hussong, Nisha C Gottfredson, Dan J Bauer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 2, 2023
Human Immunodeficiency Virus Status, Tenofovir Exposure, and the Risk of Poor Coronavirus Disease 19 Outcomes: Real-World Analysis From 6 United States Cohorts Before Vaccine RolloutAlexandra N Lea, Wendy A Leyden, Oleg Sofrygin, et al.
Frontiers in Immunology|July 11, 2022
Identification of Highly Cross-Reactive Mimotopes for a Public T Cell Response in Murine MelanomaBeth E Grace, Coralie M Backlund, Duncan M Morgan, et al.
Genome Medicine|July 30, 2015
Prospective participant selection and ranking to maximize actionable pharmacogenetic variants and discovery in the eMERGE NetworkDavid R Crosslin, Peggy D Robertson, David S Carrell, et al.
Molecular Cancer Therapeutics|October 25, 2019
A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic CancerRyan J Sullivan, Antoine Hollebecque, Keith T Flaherty, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2020
<i>BRAF</i>-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal CancerGary Middleton, Yiqun Yang, Catarina D Campbell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2012
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trialDavid C Smith, Matthew R Smith, Christopher Sweeney, et al.
Pageof 210